首页 > 最新文献

Journal of Intensive Care最新文献

英文 中文
Development and 2025 re-evaluation of a Japanese quality indicator set for adult intensive care: a modified RAND/UCLA Delphi study. 日本成人重症监护质量指标集的发展和2025年再评价:一项修改后的兰德/加州大学洛杉矶分校德尔菲研究。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-10 DOI: 10.1186/s40560-026-00863-w
Junji Kumasawa, Hiroshi Okamoto, Takaki Naito, Takehiko Asaga, Masayoshi Kimura, Toru Kotani, Yasuhiro Komatsu, Takeshi Suzuki, Tetsuya Takahashi, Tetsuhiro Takei, Masaji Nishimura, Satoru Hashimoto, Hiroko Yamaguchi, Matsuyuki Doi

Background: Quality indicators (QIs) support measurement and improvement of ICU care; however, until 2017 there was no comprehensive, evidence-based QI set tailored to frontline adult ICU practice in Japan. Because evidence and practice evolve, periodic updating is required. We developed a Japanese ICU QI set in 2017-2018 and conducted a formal re-evaluation in 2025 to confirm current validity and update the core set.

Methods: We used a modified RAND/UCLA appropriateness method. First, an initial list of candidate QIs was generated through a systematic literature review and major clinical guidelines. Next, a multidisciplinary panel of 14 Japanese experts (including intensivists, a nurse, a physiotherapist, and a clinical engineer) rated the appropriateness of these indicators using a nine-point Likert scale (Round 1). Following Round 1, a face-to-face consensus meeting was held to discuss, refine, add, or delete indicators based on scientific evidence, clinical importance, and feasibility, followed by Round 2 to finalize the 2018 consensus set. In 2025 (Round 3), the panel re-rated all indicators from the 2018 set using the same rating and classification framework and also rated newly proposed indicators reflecting contemporary practice.

Results: The systematic review yielded 44 initial candidate QIs. After the two-round rating process and the expert panel meeting, a 2018 consensus set of 38 QIs was established (13 structure indicators, 10 process indicators, and 15 outcome indicators). In Round 3 (2025), 37 indicators remained Appropriate, whereas one indicator was reclassified as Uncertain and was not retained in the updated core set. One newly proposed indicator was rated Appropriate and added, resulting in an updated 2025 core set of 38 indicators. All selected indicators were deemed appropriate and relevant for the Japanese ICU setting by the expert panel.

Conclusions: Using a rigorous modified RAND/UCLA appropriateness method and a 2025 re-evaluation, we developed and updated a feasible, contextually adapted Japanese ICU QI set. The updated core set, with operational definitions and specified data sources, provides a foundation for national benchmarking and continuous quality improvement in Japanese ICUs. 330 words.

背景:质量指标(QIs)支持ICU护理的测量和改进;然而,直到2017年,日本还没有针对一线成人ICU实践的全面的、基于证据的QI集。因为证据和实践是不断发展的,所以需要定期更新。我们于2017-2018年开发了日本ICU QI集,并于2025年进行了正式的重新评估,以确认当前的有效性并更新核心集。方法:采用改良的RAND/UCLA适宜性方法。首先,通过系统的文献回顾和主要临床指南生成候选QIs的初始列表。接下来,由14名日本专家组成的多学科小组(包括重症医师、一名护士、一名物理治疗师和一名临床工程师)使用李克特9分量表(第一轮)对这些指标的适当性进行评分。在第1轮之后,召开面对面共识会议,根据科学证据、临床重要性和可行性讨论、完善、增加或删除指标,随后举行第2轮会议,最终确定2018年共识集。在2025年(第三轮),专家组使用相同的评级和分类框架对2018年设定的所有指标进行了重新评级,并对反映当代实践的新提出的指标进行了评级。结果:系统评价产生44个初始候选QIs。经过两轮评级过程和专家小组会议,确定了2018年共识的38个QIs(13个结构指标,10个过程指标,15个结果指标)。在第三轮(2025年)中,37个指标仍然是适当的,而一个指标被重新分类为不确定,并没有保留在更新的核心集中。一项新提议的指标被评为“适当”并加以增加,从而形成更新后的2025年核心指标,其中包括38项指标。专家小组认为所有选定的指标都是适当的,与日本ICU环境相关。结论:采用严格的改进RAND/UCLA适宜性方法和2025年的重新评估,我们开发并更新了一套可行的、适合日本ICU环境的QI集。更新后的核心集具有操作定义和指定的数据源,为日本icu的国家基准和持续质量改进提供了基础。330个单词。
{"title":"Development and 2025 re-evaluation of a Japanese quality indicator set for adult intensive care: a modified RAND/UCLA Delphi study.","authors":"Junji Kumasawa, Hiroshi Okamoto, Takaki Naito, Takehiko Asaga, Masayoshi Kimura, Toru Kotani, Yasuhiro Komatsu, Takeshi Suzuki, Tetsuya Takahashi, Tetsuhiro Takei, Masaji Nishimura, Satoru Hashimoto, Hiroko Yamaguchi, Matsuyuki Doi","doi":"10.1186/s40560-026-00863-w","DOIUrl":"https://doi.org/10.1186/s40560-026-00863-w","url":null,"abstract":"<p><strong>Background: </strong>Quality indicators (QIs) support measurement and improvement of ICU care; however, until 2017 there was no comprehensive, evidence-based QI set tailored to frontline adult ICU practice in Japan. Because evidence and practice evolve, periodic updating is required. We developed a Japanese ICU QI set in 2017-2018 and conducted a formal re-evaluation in 2025 to confirm current validity and update the core set.</p><p><strong>Methods: </strong>We used a modified RAND/UCLA appropriateness method. First, an initial list of candidate QIs was generated through a systematic literature review and major clinical guidelines. Next, a multidisciplinary panel of 14 Japanese experts (including intensivists, a nurse, a physiotherapist, and a clinical engineer) rated the appropriateness of these indicators using a nine-point Likert scale (Round 1). Following Round 1, a face-to-face consensus meeting was held to discuss, refine, add, or delete indicators based on scientific evidence, clinical importance, and feasibility, followed by Round 2 to finalize the 2018 consensus set. In 2025 (Round 3), the panel re-rated all indicators from the 2018 set using the same rating and classification framework and also rated newly proposed indicators reflecting contemporary practice.</p><p><strong>Results: </strong>The systematic review yielded 44 initial candidate QIs. After the two-round rating process and the expert panel meeting, a 2018 consensus set of 38 QIs was established (13 structure indicators, 10 process indicators, and 15 outcome indicators). In Round 3 (2025), 37 indicators remained Appropriate, whereas one indicator was reclassified as Uncertain and was not retained in the updated core set. One newly proposed indicator was rated Appropriate and added, resulting in an updated 2025 core set of 38 indicators. All selected indicators were deemed appropriate and relevant for the Japanese ICU setting by the expert panel.</p><p><strong>Conclusions: </strong>Using a rigorous modified RAND/UCLA appropriateness method and a 2025 re-evaluation, we developed and updated a feasible, contextually adapted Japanese ICU QI set. The updated core set, with operational definitions and specified data sources, provides a foundation for national benchmarking and continuous quality improvement in Japanese ICUs. 330 words.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146149977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using laxative to recover intestinal function could improve the survival outcome for patients with cardiac arrest: a retrospective cohort study from MIMIC-IV database. 使用泻药恢复肠道功能可以改善心脏骤停患者的生存结果:来自MIMIC-IV数据库的回顾性队列研究。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-09 DOI: 10.1186/s40560-026-00861-y
Jingwei Duan, Yuanchao Shi, Yufan Du, Dilu Li, Baomin Duan, Guoxing Wang

Background: Despite advances in post-cardiac arrest (CA) care, mortality rates remain high. Intestinal dysfunction following CA is associated with adverse clinical outcomes. While laxatives might be a potential therapeutic strategy for restoring intestinal function, there is currently a lack of evidence.

Objective: This study aims to explore the safety and efficacy of laxatives as therapeutic agents for intestinal function recovery in CA, while further assessing the most suitable types of laxatives for this clinical context.

Methods: Utilizing the MIMIC-IV database, we conducted a retrospective cohort study categorizing patients into laxative and non-laxative groups. Propensity score matching (PSM) was applied to balance baseline characteristics. We classified confounders into prehospital and hospitalization categories, establishing three hierarchical adjustment models. Through multivariable Cox and logistic regression analyses, we assessed 30-day and extended mortality risks while evaluating laxative-associated safety outcomes. Time-dependent Cox regression analysis was utilized to assess the time-varying effect of laxative administration. Furthermore, we also comparatively analyzed the risk-benefit profiles of commonly used laxatives.

Results: 2604 patients were eligible for this study. After PSM, a total of 898 patients were average divided into two groups. Patients in the laxative group demonstrated a statistically significant reduction in 30-day mortality risk compared to the non-laxative group (HR = 0.686, 95%CI [0.550-0.855], P = 0.001). After applying time-dependent Cox regression analysis, the results remain consistent (HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001). Meanwhile, laxative did not increase the risk of sepsis and Clostridium difficile infection but improved the bowel sounds recovery and increased the ICU-free day. Further subgroup analysis revealed that the use of docusate sodium (HR = 0.753, 95%CI [0.566-1.000], P = 0.050) may be associated with a decreased mortality risk.

Conclusion: Early using laxative to improve intestinal function is associated with improved survival outcomes. However, clinical application may be guided by the bowel sounds recovery and demonstrated tolerance to enteral feeding. This still requires further studies to confirm.

背景:尽管心脏骤停(CA)后护理取得了进展,但死亡率仍然很高。CA后的肠道功能障碍与不良临床结果相关。虽然泻药可能是恢复肠道功能的潜在治疗策略,但目前缺乏证据。目的:本研究旨在探讨泻药作为CA肠道功能恢复治疗药物的安全性和有效性,同时进一步评估最适合这种临床情况的泻药类型。方法:利用MIMIC-IV数据库进行回顾性队列研究,将患者分为泻药组和非泻药组。倾向评分匹配(PSM)用于平衡基线特征。我们将混杂因素分为院前和住院两类,建立了三种层次调整模型。通过多变量Cox和逻辑回归分析,我们评估了30天和延长的死亡风险,同时评估了泻药相关的安全性结果。采用时变Cox回归分析评估通便药的时变效应。此外,我们还比较分析了常用泻药的风险-收益概况。结果:2604例患者符合本研究的条件。经PSM治疗后,898例患者平均分为两组。通便药组患者30天死亡风险较未通便药组有统计学意义的降低(HR = 0.686, 95%CI [0.550-0.855], P = 0.001)。应用时间相关Cox回归分析后,结果一致(HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001)。同时,泻药没有增加脓毒症和艰难梭菌感染的风险,但改善了肠音恢复,增加了无icu天数。进一步的亚组分析显示,使用docusate钠(HR = 0.753, 95%CI [0.566-1.000], P = 0.050)可能与降低死亡风险相关。结论:早期使用泻药改善肠道功能与改善生存预后相关。然而,临床应用可能以肠音恢复和肠内喂养耐受性为指导。这还需要进一步的研究来证实。
{"title":"Using laxative to recover intestinal function could improve the survival outcome for patients with cardiac arrest: a retrospective cohort study from MIMIC-IV database.","authors":"Jingwei Duan, Yuanchao Shi, Yufan Du, Dilu Li, Baomin Duan, Guoxing Wang","doi":"10.1186/s40560-026-00861-y","DOIUrl":"https://doi.org/10.1186/s40560-026-00861-y","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in post-cardiac arrest (CA) care, mortality rates remain high. Intestinal dysfunction following CA is associated with adverse clinical outcomes. While laxatives might be a potential therapeutic strategy for restoring intestinal function, there is currently a lack of evidence.</p><p><strong>Objective: </strong>This study aims to explore the safety and efficacy of laxatives as therapeutic agents for intestinal function recovery in CA, while further assessing the most suitable types of laxatives for this clinical context.</p><p><strong>Methods: </strong>Utilizing the MIMIC-IV database, we conducted a retrospective cohort study categorizing patients into laxative and non-laxative groups. Propensity score matching (PSM) was applied to balance baseline characteristics. We classified confounders into prehospital and hospitalization categories, establishing three hierarchical adjustment models. Through multivariable Cox and logistic regression analyses, we assessed 30-day and extended mortality risks while evaluating laxative-associated safety outcomes. Time-dependent Cox regression analysis was utilized to assess the time-varying effect of laxative administration. Furthermore, we also comparatively analyzed the risk-benefit profiles of commonly used laxatives.</p><p><strong>Results: </strong>2604 patients were eligible for this study. After PSM, a total of 898 patients were average divided into two groups. Patients in the laxative group demonstrated a statistically significant reduction in 30-day mortality risk compared to the non-laxative group (HR = 0.686, 95%CI [0.550-0.855], P = 0.001). After applying time-dependent Cox regression analysis, the results remain consistent (HR = - 0.771 + 0.632 × ln[day + 1], 95%CI [0.528-0.835], P = 0.001). Meanwhile, laxative did not increase the risk of sepsis and Clostridium difficile infection but improved the bowel sounds recovery and increased the ICU-free day. Further subgroup analysis revealed that the use of docusate sodium (HR = 0.753, 95%CI [0.566-1.000], P = 0.050) may be associated with a decreased mortality risk.</p><p><strong>Conclusion: </strong>Early using laxative to improve intestinal function is associated with improved survival outcomes. However, clinical application may be guided by the bowel sounds recovery and demonstrated tolerance to enteral feeding. This still requires further studies to confirm.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146150001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-weighted lactate and glucose-lactate ratio outperform static values in ICU mortality prediction after traumatic brain injury: a retrospective cohort study. 时间加权乳酸和葡萄糖-乳酸比值在预测创伤性脑损伤后ICU死亡率方面优于静态值:一项回顾性队列研究。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-07 DOI: 10.1186/s40560-026-00864-9
Matthias Manfred Deininger, Magdalena Ralser, Nico Haehn, Marius Huehn, Dmitrij Ziles, Gernot Marx, Catharina Conzen-Dilger, Anke Hoellig, Thomas Breuer

Background: Traumatic brain injury (TBI) is a major cause of trauma-related deaths. Systemic glucose and lactate levels reflect secondary metabolic derangements over time; however, most prognostic models rely on admission values. This study compared static and longitudinal indices of glucose, lactate, and their ratio in relation to ICU mortality.

Methods: This retrospective single-center study analyzed 479 non-diabetic adult patients with TBI admitted to a German university ICU (2013-2023). After 1:2 severity-balanced, outcome-stratified propensity score matching, 229 patients (150 survivors, 79 non-survivors) were included. Indices comprised admission values, means, clearance, time-weighted averages, variability, and dysglycemic burden. Outcome was ICU mortality, assessed using regression, mixed-effects modeling, and ROC analysis.

Results: Longitudinal indices showed stronger associations. Time-weighted average lactate was the best independent predictor (OR 14.70, 95% CI [5.41-39.98], p < 0.001, AUC 0.73). Time-weighted average glucose-lactate ratio also independently predicted ICU mortality (OR 0.75, 95% CI [0.66-0.86], p < 0.001). Non-survivors exhibited persistently higher glucose, lactate and lower ratios, with lactate significantly elevated on all first ten ICU days (all p < 0.05). Admission values, clearance and variability were not predictive after adjustment.

Conclusions: In critically ill non-diabetic patients with TBI, longitudinal time-weighted average lactate significantly outperformed admission values and glucose metrics for predicting ICU mortality in a severity-balanced cohort; the glucose-lactate ratio was associated but did not surpass lactate. These findings underscore the importance of longitudinal monitoring and support prioritizing lactate in multiparametric prognostic model to account for secondary injuries. Prospective validation is warranted to confirm external validity and assess therapeutic implications.

背景:创伤性脑损伤(TBI)是创伤相关死亡的主要原因。随着时间的推移,全身葡萄糖和乳酸水平反映继发性代谢紊乱;然而,大多数预后模型依赖于入院值。本研究比较了葡萄糖、乳酸的静态和纵向指标及其与ICU死亡率的关系。方法:本回顾性单中心研究分析了2013-2023年德国一所大学ICU收治的479例非糖尿病成年TBI患者。经1:2严重程度平衡、结果分层倾向评分匹配后,纳入229例患者(150例幸存者,79例非幸存者)。指标包括入院值、平均值、清除率、时间加权平均值、变异性和血糖异常负担。结果是ICU死亡率,采用回归、混合效应建模和ROC分析进行评估。结果:纵向指标相关性较强。时间加权平均乳酸是最好的独立预测因子(OR 14.70, 95% CI [5.41-39.98], p结论:在严重程度平衡的队列中,危重非糖尿病TBI患者,纵向时间加权平均乳酸显著优于入院值和血糖指标,预测ICU死亡率;葡萄糖-乳酸比值相关,但不超过乳酸。这些发现强调了纵向监测的重要性,并支持在多参数预后模型中优先考虑乳酸水平以解释继发性损伤。前瞻性验证是必要的,以确认外部有效性和评估治疗意义。
{"title":"Time-weighted lactate and glucose-lactate ratio outperform static values in ICU mortality prediction after traumatic brain injury: a retrospective cohort study.","authors":"Matthias Manfred Deininger, Magdalena Ralser, Nico Haehn, Marius Huehn, Dmitrij Ziles, Gernot Marx, Catharina Conzen-Dilger, Anke Hoellig, Thomas Breuer","doi":"10.1186/s40560-026-00864-9","DOIUrl":"https://doi.org/10.1186/s40560-026-00864-9","url":null,"abstract":"<p><strong>Background: </strong>Traumatic brain injury (TBI) is a major cause of trauma-related deaths. Systemic glucose and lactate levels reflect secondary metabolic derangements over time; however, most prognostic models rely on admission values. This study compared static and longitudinal indices of glucose, lactate, and their ratio in relation to ICU mortality.</p><p><strong>Methods: </strong>This retrospective single-center study analyzed 479 non-diabetic adult patients with TBI admitted to a German university ICU (2013-2023). After 1:2 severity-balanced, outcome-stratified propensity score matching, 229 patients (150 survivors, 79 non-survivors) were included. Indices comprised admission values, means, clearance, time-weighted averages, variability, and dysglycemic burden. Outcome was ICU mortality, assessed using regression, mixed-effects modeling, and ROC analysis.</p><p><strong>Results: </strong>Longitudinal indices showed stronger associations. Time-weighted average lactate was the best independent predictor (OR 14.70, 95% CI [5.41-39.98], p < 0.001, AUC 0.73). Time-weighted average glucose-lactate ratio also independently predicted ICU mortality (OR 0.75, 95% CI [0.66-0.86], p < 0.001). Non-survivors exhibited persistently higher glucose, lactate and lower ratios, with lactate significantly elevated on all first ten ICU days (all p < 0.05). Admission values, clearance and variability were not predictive after adjustment.</p><p><strong>Conclusions: </strong>In critically ill non-diabetic patients with TBI, longitudinal time-weighted average lactate significantly outperformed admission values and glucose metrics for predicting ICU mortality in a severity-balanced cohort; the glucose-lactate ratio was associated but did not surpass lactate. These findings underscore the importance of longitudinal monitoring and support prioritizing lactate in multiparametric prognostic model to account for secondary injuries. Prospective validation is warranted to confirm external validity and assess therapeutic implications.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fentanyl as an induction agent for tracheal intubation in critically ill patients: a systematic review and meta-analysis. 芬太尼作为危重患者气管插管诱导剂:系统回顾和荟萃分析。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-07 DOI: 10.1186/s40560-026-00866-7
Yuki Kotani, Takatoshi Koroki, Takeshi Nomura, Yoshiro Hayashi

Background: Tracheal intubation in critically ill adults is frequently complicated by severe physiological adverse events, particularly cardiovascular instability. Although fentanyl is commonly used for induction, observational data suggest that its use may increase the risk of post-intubation hypotension. However, the overall randomized evidence remains unclear. In this systematic review and meta-analysis of randomized controlled trials (RCTs), we hypothesized that induction regimens including fentanyl or its analogs would increase the risk of peri-intubation cardiovascular instability in critically ill patients.

Methods: We comprehensively searched PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP from inception through October 31, 2025. Eligible studies were RCTs comparing an induction regimen including fentanyl or its analogs with one without them in critically ill adults undergoing tracheal intubation. The primary outcome was peri-intubation cardiovascular instability. Secondary outcomes included peri-intubation hypoxemia, successful intubation on the first attempt, duration of mechanical ventilation, ICU length of stay, and mortality. Random-effects meta-analyses were performed for all outcomes. Trial sequential analysis (TSA) was conducted for the primary outcome. Certainty of evidence was assessed using the GRADE approach.

Results: We included five RCTs and 515 participants. Two studies were judged to be low risk of bias, two raised some concerns, and one was at high risk of bias. Comparators included various induction agents and placebo. Definitions of peri-intubation cardiovascular instability also varied. The evidence was very uncertain regarding the effect of fentanyl on the risk of peri-intubation cardiovascular instability (risk ratio, 1.41; 95% confidence interval, 0.83-2.40; risk difference, 9.2% more; 95% confidence interval, 3.8% fewer to 31.3% more; very low certainty). In TSA, the required information size (n = 5586) was not reached, indicating the lack of statistical power. The certainty of evidence for pooled secondary outcomes was generally low or very low.

Conclusions: The effect of fentanyl on peri-intubation cardiovascular instability remains highly uncertain, with pooled estimates compatible with substantial harm, substantial benefit, or no effect. Current randomized evidence is insufficient to guide routine clinical practice, given their very low or low certainty and susceptibility to random error.

Trial registration: PROSPERO (registration number: CRD420251241214).

背景:危重成人气管插管经常并发严重的生理不良事件,特别是心血管不稳定。虽然芬太尼通常用于诱导,但观察数据表明,芬太尼的使用可能增加插管后低血压的风险。然而,总体随机证据仍不清楚。在这项随机对照试验(RCTs)的系统回顾和荟萃分析中,我们假设包括芬太尼或其类似物在内的诱导方案会增加危重患者插管期心血管不稳定的风险。方法:我们综合检索了PubMed、Embase、Cochrane图书馆、ClinicalTrials.gov和WHO ICTRP从成立到2025年10月31日的数据库。符合条件的研究是比较含有芬太尼或其类似物的诱导方案与不含芬太尼的诱导方案在气管插管的危重成人中的随机对照试验。主要结局是插管期心血管不稳定。次要结局包括插管周围低氧血症、第一次插管成功、机械通气持续时间、ICU住院时间和死亡率。对所有结果进行随机效应荟萃分析。对主要结局进行试验序贯分析(TSA)。使用GRADE方法评估证据的确定性。结果:我们纳入5项随机对照试验,515名受试者。两项研究被判定为低偏倚风险,两项研究引起了一些关注,一项研究具有高偏倚风险。比较物包括各种诱导剂和安慰剂。插管期心血管不稳定的定义也各不相同。关于芬太尼对插管期心血管不稳定风险的影响,证据非常不确定(风险比为1.41;95%可信区间为0.83-2.40;风险差为9.2%;95%可信区间为3.8% - 31.3%;确定性非常低)。在TSA中,没有达到要求的信息大小(n = 5586),说明统计能力不足。合并次要结局的证据确定性一般较低或非常低。结论:芬太尼对插管期心血管不稳定的影响仍然高度不确定,综合估计结果与重大危害、重大益处或无影响相一致。目前的随机证据还不足以指导常规临床实践,因为它们的确定性很低或很低,而且容易出现随机错误。试验注册:PROSPERO(注册号:CRD420251241214)。
{"title":"Fentanyl as an induction agent for tracheal intubation in critically ill patients: a systematic review and meta-analysis.","authors":"Yuki Kotani, Takatoshi Koroki, Takeshi Nomura, Yoshiro Hayashi","doi":"10.1186/s40560-026-00866-7","DOIUrl":"https://doi.org/10.1186/s40560-026-00866-7","url":null,"abstract":"<p><strong>Background: </strong>Tracheal intubation in critically ill adults is frequently complicated by severe physiological adverse events, particularly cardiovascular instability. Although fentanyl is commonly used for induction, observational data suggest that its use may increase the risk of post-intubation hypotension. However, the overall randomized evidence remains unclear. In this systematic review and meta-analysis of randomized controlled trials (RCTs), we hypothesized that induction regimens including fentanyl or its analogs would increase the risk of peri-intubation cardiovascular instability in critically ill patients.</p><p><strong>Methods: </strong>We comprehensively searched PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the WHO ICTRP from inception through October 31, 2025. Eligible studies were RCTs comparing an induction regimen including fentanyl or its analogs with one without them in critically ill adults undergoing tracheal intubation. The primary outcome was peri-intubation cardiovascular instability. Secondary outcomes included peri-intubation hypoxemia, successful intubation on the first attempt, duration of mechanical ventilation, ICU length of stay, and mortality. Random-effects meta-analyses were performed for all outcomes. Trial sequential analysis (TSA) was conducted for the primary outcome. Certainty of evidence was assessed using the GRADE approach.</p><p><strong>Results: </strong>We included five RCTs and 515 participants. Two studies were judged to be low risk of bias, two raised some concerns, and one was at high risk of bias. Comparators included various induction agents and placebo. Definitions of peri-intubation cardiovascular instability also varied. The evidence was very uncertain regarding the effect of fentanyl on the risk of peri-intubation cardiovascular instability (risk ratio, 1.41; 95% confidence interval, 0.83-2.40; risk difference, 9.2% more; 95% confidence interval, 3.8% fewer to 31.3% more; very low certainty). In TSA, the required information size (n = 5586) was not reached, indicating the lack of statistical power. The certainty of evidence for pooled secondary outcomes was generally low or very low.</p><p><strong>Conclusions: </strong>The effect of fentanyl on peri-intubation cardiovascular instability remains highly uncertain, with pooled estimates compatible with substantial harm, substantial benefit, or no effect. Current randomized evidence is insufficient to guide routine clinical practice, given their very low or low certainty and susceptibility to random error.</p><p><strong>Trial registration: </strong>PROSPERO (registration number: CRD420251241214).</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External ventricular drain-related meningitis: prediction model or early diagnostic tool? 外脑室漏相关性脑膜炎:预测模型还是早期诊断工具?
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-03 DOI: 10.1186/s40560-025-00842-7
Muhammad Mohsin Sami, Ruqaiya Muhammad Naeem, Imran Zahid
{"title":"External ventricular drain-related meningitis: prediction model or early diagnostic tool?","authors":"Muhammad Mohsin Sami, Ruqaiya Muhammad Naeem, Imran Zahid","doi":"10.1186/s40560-025-00842-7","DOIUrl":"10.1186/s40560-025-00842-7","url":null,"abstract":"","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"14 1","pages":"12"},"PeriodicalIF":4.7,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12869999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases. 败血症患者抗凝血酶水平与预后的关系:基于MIMIC-IV和MIMIC-III数据库的回顾性队列研究
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-02-02 DOI: 10.1186/s40560-026-00862-x
Bingkui Ren, Gang Zhou, Haiyan Xue, Siying Chen, Yuping Zhang, Guangjie Wang, Fengxue Zhu

Background: Sepsis is a critical determinant of mortality in critical patients. Antithrombin (AT) plays a pivotal role as a serine protease inhibitor with dual anticoagulant and anti-inflammatory functions, yet its precise role in prognostic stratification remains undefined. This study aimed to investigate the association between AT activity and clinical outcomes in sepsis and to identify critical prognostic thresholds.

Methods: We conducted a retrospective cohort study of 222 septic patients from the MIMIC-IV and MIMIC-III databases. AT activity was measured within the first 24 h following sepsis diagnosis, with the primary outcome defined as 28-day all-cause mortality. For preliminary description, AT activity was categorized into tertiles. The primary analysis utilized restricted cubic splines (RCS) to model the dose-response relationship and identify risk thresholds. Multivariable Cox regression models were employed to adjust for demographics, comorbidities, and SOFA score. Subgroup and survival analyses were performed to evaluate effect modification and visualize outcome differences across threshold-defined risk groups. To visually compare survival outcomes between patient groups defined by the RCS-derived risk thresholds, we generated Kaplan-Meier curves and employed log-rank tests.

Results: A non-linear relationship between AT activity and 28-day mortality was identified, with a marked increase in risk observed below approximately 55% in the overall cohort. Patients with AT activity < 55% had significantly higher 28-day mortality (34.2% vs. 14.4%, p = 0.001), ICU mortality (33.3% vs. 9.0%, p < 0.001), and incidences of disseminated intravascular coagulation (DIC) (22.5% vs. 3.6%, p < 0.001) and acute kidney injury (AKI) (78.4% vs. 62.2%, p = 0.013). Subgroup analysis revealed a significant interaction with hypertension. In the hypertensive subgroup, a similarly elevated risk zone was observed below approximately 64% AT activity. Hypertensive patients below this level had markedly increased 28-day mortality (42.3% vs. 9.62%, p < 0.001), ICU mortality (38.5% vs. 5.77%, p < 0.001), and incidences of DIC (19.2% vs. 1.92%, p < 0.001).

Conclusion: Reduced AT activity was significantly associated with higher mortality and organ dysfunction in sepsis. Risk thresholds were observed at approximately 55% for the overall cohort and 64% among hypertensive patients. Patients below these levels exhibited significantly increased mortality and higher incidences of DIC and AKI. These findings support AT activity as a prognostic biomarker for risk stratification and highlight its potential to inform future management strategies for high-risk patients.

背景:脓毒症是危重患者死亡率的关键决定因素。抗凝血酶(AT)作为丝氨酸蛋白酶抑制剂具有抗凝和抗炎双重功能,但其在预后分层中的确切作用尚不清楚。本研究旨在探讨AT活性与败血症临床结果之间的关系,并确定关键预后阈值。方法:我们对来自MIMIC-IV和MIMIC-III数据库的222例脓毒症患者进行回顾性队列研究。在败血症诊断后的前24小时内测量AT活性,主要结局定义为28天全因死亡率。为了进行初步描述,将AT活性分为三类。初步分析利用限制性三次样条(RCS)来建立剂量-反应关系模型并确定风险阈值。采用多变量Cox回归模型调整人口统计学、合并症和SOFA评分。进行亚组和生存分析,以评估阈值定义的风险组之间的效果修改和可视化结果差异。为了直观地比较由rcs衍生的风险阈值定义的患者组之间的生存结果,我们生成了Kaplan-Meier曲线并采用对数秩检验。结果:确定了AT活动与28天死亡率之间的非线性关系,在整个队列中观察到风险显著增加,低于约55%。结论:AT活性降低与败血症患者较高的死亡率和器官功能障碍显著相关。整个队列的风险阈值约为55%,高血压患者的风险阈值约为64%。低于这些水平的患者死亡率显著增加,DIC和AKI的发生率也较高。这些发现支持AT活性作为风险分层的预后生物标志物,并强调其为高风险患者的未来管理策略提供信息的潜力。
{"title":"Association between antithrombin levels and prognosis in patients with sepsis: a retrospective cohort study based on the MIMIC-IV and MIMIC-III databases.","authors":"Bingkui Ren, Gang Zhou, Haiyan Xue, Siying Chen, Yuping Zhang, Guangjie Wang, Fengxue Zhu","doi":"10.1186/s40560-026-00862-x","DOIUrl":"https://doi.org/10.1186/s40560-026-00862-x","url":null,"abstract":"<p><strong>Background: </strong>Sepsis is a critical determinant of mortality in critical patients. Antithrombin (AT) plays a pivotal role as a serine protease inhibitor with dual anticoagulant and anti-inflammatory functions, yet its precise role in prognostic stratification remains undefined. This study aimed to investigate the association between AT activity and clinical outcomes in sepsis and to identify critical prognostic thresholds.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of 222 septic patients from the MIMIC-IV and MIMIC-III databases. AT activity was measured within the first 24 h following sepsis diagnosis, with the primary outcome defined as 28-day all-cause mortality. For preliminary description, AT activity was categorized into tertiles. The primary analysis utilized restricted cubic splines (RCS) to model the dose-response relationship and identify risk thresholds. Multivariable Cox regression models were employed to adjust for demographics, comorbidities, and SOFA score. Subgroup and survival analyses were performed to evaluate effect modification and visualize outcome differences across threshold-defined risk groups. To visually compare survival outcomes between patient groups defined by the RCS-derived risk thresholds, we generated Kaplan-Meier curves and employed log-rank tests.</p><p><strong>Results: </strong>A non-linear relationship between AT activity and 28-day mortality was identified, with a marked increase in risk observed below approximately 55% in the overall cohort. Patients with AT activity < 55% had significantly higher 28-day mortality (34.2% vs. 14.4%, p = 0.001), ICU mortality (33.3% vs. 9.0%, p < 0.001), and incidences of disseminated intravascular coagulation (DIC) (22.5% vs. 3.6%, p < 0.001) and acute kidney injury (AKI) (78.4% vs. 62.2%, p = 0.013). Subgroup analysis revealed a significant interaction with hypertension. In the hypertensive subgroup, a similarly elevated risk zone was observed below approximately 64% AT activity. Hypertensive patients below this level had markedly increased 28-day mortality (42.3% vs. 9.62%, p < 0.001), ICU mortality (38.5% vs. 5.77%, p < 0.001), and incidences of DIC (19.2% vs. 1.92%, p < 0.001).</p><p><strong>Conclusion: </strong>Reduced AT activity was significantly associated with higher mortality and organ dysfunction in sepsis. Risk thresholds were observed at approximately 55% for the overall cohort and 64% among hypertensive patients. Patients below these levels exhibited significantly increased mortality and higher incidences of DIC and AKI. These findings support AT activity as a prognostic biomarker for risk stratification and highlight its potential to inform future management strategies for high-risk patients.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146105931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severe community-acquired pneumonia: an integral approach. 严重社区获得性肺炎:综合方法。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-01-31 DOI: 10.1186/s40560-026-00854-x
Arsah Asis, Darren McMahon, Shigeki Fujitani, Pedro Povoa, Alejandro Rodriguez, Luis Felipe Reyes, Ignacio Martin-Loeches
<p><strong>Background: </strong>Severe community-acquired pneumonia represents the most critical manifestation of pneumonia acquired outside the hospital and remains a major cause of intensive care admission and death worldwide. It is frequently complicated by acute respiratory failure, circulatory shock, and multiple organ dysfunction, with mortality commonly exceeding 25-40%. Despite progress in vaccination programmes, microbiological diagnostics, and critical care support, major uncertainties persist regarding early recognition, pathogen identification, antimicrobial selection and duration, management of co-infections, and assessment of treatment response. These challenges are amplified by increasing host heterogeneity and antimicrobial resistance.</p><p><strong>Main body: </strong>Contemporary epidemiological studies consistently demonstrate that mortality in severe community-acquired pneumonia is closely linked to the severity of organ dysfunction rather than to pulmonary involvement alone. In response, the recent international guideline definitions incorporate both respiratory and systemic criteria to standardise identification and guide early triage. However, these frameworks also reveal substantial variability related to host factors that influence clinical presentation, microbiological findings, and outcomes. Advanced age, sex, chronic cardiopulmonary disease, diabetes, frailty, and prior healthcare exposure modify risk, while immunocompromised populations-including transplant recipients, patients with malignancy, individuals receiving immunomodulatory therapies, and people living with Human Immunodeficiency Virus in resource-limited settings-face distinct diagnostic and therapeutic challenges. Accurate microbiological diagnosis remains difficult, with mixed or unidentified infections frequently encountered. Structured respiratory sampling and molecular diagnostic techniques, particularly lower respiratory tract multiplex polymerase chain reaction panels, have improved pathogen detection and support earlier optimisation of antimicrobial therapy. Biomarkers such as procalcitonin and C-reactive protein provide complementary information on disease trajectory and response to treatment, enabling more confident reassessment and earlier discontinuation of antibiotics when aligned with clinical improvement. Severity stratification using combined clinical scores, radiological extent, and laboratory markers refines prognostication and informs treatment intensity. Empiric antimicrobial therapy should be initiated promptly and individualised according to patient-specific risk factors for resistant pathogens, with systematic reassessment within 24-48 h. Adjunctive strategies, including advanced respiratory and haemodynamic support, corticosteroids in selected inflammatory phenotypes, and emerging host-directed therapies such as intravenous immunoglobulins, form part of a personalised management approach.</p><p><strong>Conclusions: </strong>An integra
背景:严重社区获得性肺炎是医院外获得性肺炎最重要的表现,在世界范围内仍然是重症监护住院和死亡的主要原因。它经常并发急性呼吸衰竭、循环休克和多器官功能障碍,死亡率通常超过25-40%。尽管在疫苗接种规划、微生物诊断和重症监护支持方面取得了进展,但在早期识别、病原体鉴定、抗菌药物的选择和持续时间、合并感染的管理以及治疗反应评估方面仍然存在重大不确定性。宿主异质性和抗菌素耐药性的增加加剧了这些挑战。当代流行病学研究一致表明,严重社区获得性肺炎的死亡率与器官功能障碍的严重程度密切相关,而不仅仅与肺部受累有关。作为回应,最近的国际指南定义纳入了呼吸和全身标准,以标准化识别和指导早期分诊。然而,这些框架也揭示了与影响临床表现、微生物学发现和结果的宿主因素相关的实质性变异性。高龄、性别、慢性心肺疾病、糖尿病、虚弱和先前的医疗保健暴露会改变风险,而免疫功能低下的人群——包括移植接受者、恶性肿瘤患者、接受免疫调节疗法的个体和资源有限的人类免疫缺陷病毒感染者——面临着独特的诊断和治疗挑战。准确的微生物诊断仍然很困难,经常遇到混合或不明感染。结构化呼吸采样和分子诊断技术,特别是下呼吸道多重聚合酶链反应面板,改善了病原体检测并支持早期优化抗菌治疗。生物标志物如降钙素原和c反应蛋白提供了疾病轨迹和治疗反应的补充信息,当与临床改善相一致时,可以更自信地重新评估和早期停药。使用综合临床评分、放射学程度和实验室标记物进行严重程度分层可以改善预后并告知治疗强度。应根据耐药病原体的患者特异性风险因素迅速启动经经验抗菌治疗,并在24-48小时内进行系统重新评估。辅助策略,包括高级呼吸和血流动力学支持,选择炎症表型的皮质类固醇,以及新兴的宿主导向治疗,如静脉注射免疫球蛋白,构成个性化管理方法的一部分。结论:将早期识别、诊断准确性、严重程度评估和个性化治疗联系起来的综合多学科战略为改善严重社区获得性肺炎的结局和促进负责任地使用抗菌药物提供了一致的途径。
{"title":"Severe community-acquired pneumonia: an integral approach.","authors":"Arsah Asis, Darren McMahon, Shigeki Fujitani, Pedro Povoa, Alejandro Rodriguez, Luis Felipe Reyes, Ignacio Martin-Loeches","doi":"10.1186/s40560-026-00854-x","DOIUrl":"https://doi.org/10.1186/s40560-026-00854-x","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Severe community-acquired pneumonia represents the most critical manifestation of pneumonia acquired outside the hospital and remains a major cause of intensive care admission and death worldwide. It is frequently complicated by acute respiratory failure, circulatory shock, and multiple organ dysfunction, with mortality commonly exceeding 25-40%. Despite progress in vaccination programmes, microbiological diagnostics, and critical care support, major uncertainties persist regarding early recognition, pathogen identification, antimicrobial selection and duration, management of co-infections, and assessment of treatment response. These challenges are amplified by increasing host heterogeneity and antimicrobial resistance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main body: &lt;/strong&gt;Contemporary epidemiological studies consistently demonstrate that mortality in severe community-acquired pneumonia is closely linked to the severity of organ dysfunction rather than to pulmonary involvement alone. In response, the recent international guideline definitions incorporate both respiratory and systemic criteria to standardise identification and guide early triage. However, these frameworks also reveal substantial variability related to host factors that influence clinical presentation, microbiological findings, and outcomes. Advanced age, sex, chronic cardiopulmonary disease, diabetes, frailty, and prior healthcare exposure modify risk, while immunocompromised populations-including transplant recipients, patients with malignancy, individuals receiving immunomodulatory therapies, and people living with Human Immunodeficiency Virus in resource-limited settings-face distinct diagnostic and therapeutic challenges. Accurate microbiological diagnosis remains difficult, with mixed or unidentified infections frequently encountered. Structured respiratory sampling and molecular diagnostic techniques, particularly lower respiratory tract multiplex polymerase chain reaction panels, have improved pathogen detection and support earlier optimisation of antimicrobial therapy. Biomarkers such as procalcitonin and C-reactive protein provide complementary information on disease trajectory and response to treatment, enabling more confident reassessment and earlier discontinuation of antibiotics when aligned with clinical improvement. Severity stratification using combined clinical scores, radiological extent, and laboratory markers refines prognostication and informs treatment intensity. Empiric antimicrobial therapy should be initiated promptly and individualised according to patient-specific risk factors for resistant pathogens, with systematic reassessment within 24-48 h. Adjunctive strategies, including advanced respiratory and haemodynamic support, corticosteroids in selected inflammatory phenotypes, and emerging host-directed therapies such as intravenous immunoglobulins, form part of a personalised management approach.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;An integra","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146097131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing infection management after cardiac arrest: addressing diagnostic uncertainty and therapeutic dilemmas-a narrative review. 心脏骤停后优化感染管理:解决诊断不确定性和治疗困境-叙述回顾。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-01-28 DOI: 10.1186/s40560-026-00859-6
Jun Hagiwara, Keitaro Yoshioka, Kanako Ito-Hagiwara, Yusuke Endo, Daniel Jafari, Daniel M Rolston, Cyrus E Kuschner, Lance B Becker, Kei Hayashida

Infections are frequent after cardiac arrest and materially affect post-ICU care and outcomes. Diagnostic uncertainty is heightened by post-cardiac arrest syndrome (PCAS)-hypoxic-ischemic brain injury, myocardial dysfunction, systemic ischemia-reperfusion injury, and immune dysregulation-and by sedation and targeted temperature management (TTM), which can mask clinical signs and modulate host defenses. Pneumonia predominates; bloodstream infection and intra-abdominal or hepatobiliary infections are under-recognized, especially in device-dependent or extracorporeal membrane oxygenation (ECMO)-treated patients. Conventional biomarkers such as C-reactive protein and procalcitonin show reduced infection specificity early after return of spontaneous circulation; therefore, single timepoint cutoffs are unreliable, and serial trajectories interpreted with clinical examination, microbiology, and imaging are preferred. Risk scores (e.g., Sequential Organ Failure Assessment [SOFA], Clinical Pulmonary Infection Score [CPIS]) may support stratification but are insufficient for definitive diagnosis. Observational cohorts report higher pneumonia rates with TTM, and temperature control can blunt fever and leukocytosis and alter cytokine and biomarker kinetics, complicating timely recognition. Prevention should emphasize protocolized bundles, including hand hygiene and asepsis, head-of-bed elevation, structured oral care per local policy, minimization of sedation with spontaneous breathing trials, and early removal of unnecessary devices, within an antimicrobial stewardship framework that supports early de-escalation once cultures and trajectories clarify etiology. Procalcitonin-guided early discontinuation reduces antibiotic exposure in general critical-care populations; in PCAS, use should prioritize serial trends integrated with clinical context rather than single thresholds. No fixed algorithm is prescribed; instead, practical considerations are presented to guide diagnostic practice, emphasizing early microbiological sampling and imaging, integration of serial biomarker trajectories with clinical assessment, and timely de-escalation as the clinical picture clarifies, without endorsing single-test cutoffs. Priorities include quantifying infection-attributable morbidity and mortality; developing and validating PCAS-specific biomarkers and composite decision tools, including electronic health record-based early warning models; evaluating short post-intubation prophylaxis in selected high-risk patients; optimizing TTM parameters (target temperature, duration, rewarming rate); and systematically characterizing under-recognized infections. A protocol-driven, multimodal program that integrates prevention, standardized diagnostics, and stewardship is required to deliver timely, appropriate therapy and improve outcomes after cardiac arrest.

感染在心脏骤停后很常见,并严重影响icu后护理和预后。心脏骤停后综合征(PCAS)——缺氧缺血性脑损伤、心肌功能障碍、全身缺血再灌注损伤和免疫失调——以及镇静和靶向温度管理(TTM)会增加诊断的不确定性,这可以掩盖临床症状并调节宿主防御。肺炎主导;血流感染和腹腔内或肝胆感染未被充分认识,特别是在器械依赖或体外膜氧合(ECMO)治疗的患者中。常规生物标志物,如c反应蛋白和降钙素原,在自然循环恢复后早期显示感染特异性降低;因此,单一时间点的截止是不可靠的,而通过临床检查、微生物学和影像学来解释序列轨迹是首选。风险评分(如顺序器官衰竭评估[SOFA]、临床肺部感染评分[CPIS])可能支持分层,但不足以进行明确诊断。观察性队列报告TTM的肺炎发生率较高,温度控制可以减弱发烧和白细胞增多,改变细胞因子和生物标志物动力学,使及时识别复杂化。预防应强调有协议的一揽子措施,包括手部卫生和无菌、床头抬高、根据当地政策进行有组织的口腔护理、在自发呼吸试验中最大限度地减少镇静,以及在抗菌药物管理框架内早期移除不必要的装置,该框架支持在培养和轨迹明确病因后早期降低剂量。降钙素原引导下的早期停药减少了一般重症监护人群的抗生素暴露;在PCAS中,应优先考虑结合临床情况的系列趋势,而不是单一阈值。没有规定固定的算法;相反,本文提出了指导诊断实践的实际考虑,强调早期微生物采样和成像,将系列生物标志物轨迹与临床评估相结合,并在临床情况明确时及时降级,而不支持单一测试的截止日期。优先事项包括量化感染导致的发病率和死亡率;开发和验证pas特异性生物标志物和综合决策工具,包括基于电子健康记录的早期预警模型;高危患者插管后短期预防的评估优化TTM参数(目标温度、持续时间、复温率);并系统地描述未被识别的感染。需要一个协议驱动的多模式项目,将预防、标准化诊断和管理相结合,以提供及时、适当的治疗并改善心脏骤停后的结果。
{"title":"Optimizing infection management after cardiac arrest: addressing diagnostic uncertainty and therapeutic dilemmas-a narrative review.","authors":"Jun Hagiwara, Keitaro Yoshioka, Kanako Ito-Hagiwara, Yusuke Endo, Daniel Jafari, Daniel M Rolston, Cyrus E Kuschner, Lance B Becker, Kei Hayashida","doi":"10.1186/s40560-026-00859-6","DOIUrl":"https://doi.org/10.1186/s40560-026-00859-6","url":null,"abstract":"<p><p>Infections are frequent after cardiac arrest and materially affect post-ICU care and outcomes. Diagnostic uncertainty is heightened by post-cardiac arrest syndrome (PCAS)-hypoxic-ischemic brain injury, myocardial dysfunction, systemic ischemia-reperfusion injury, and immune dysregulation-and by sedation and targeted temperature management (TTM), which can mask clinical signs and modulate host defenses. Pneumonia predominates; bloodstream infection and intra-abdominal or hepatobiliary infections are under-recognized, especially in device-dependent or extracorporeal membrane oxygenation (ECMO)-treated patients. Conventional biomarkers such as C-reactive protein and procalcitonin show reduced infection specificity early after return of spontaneous circulation; therefore, single timepoint cutoffs are unreliable, and serial trajectories interpreted with clinical examination, microbiology, and imaging are preferred. Risk scores (e.g., Sequential Organ Failure Assessment [SOFA], Clinical Pulmonary Infection Score [CPIS]) may support stratification but are insufficient for definitive diagnosis. Observational cohorts report higher pneumonia rates with TTM, and temperature control can blunt fever and leukocytosis and alter cytokine and biomarker kinetics, complicating timely recognition. Prevention should emphasize protocolized bundles, including hand hygiene and asepsis, head-of-bed elevation, structured oral care per local policy, minimization of sedation with spontaneous breathing trials, and early removal of unnecessary devices, within an antimicrobial stewardship framework that supports early de-escalation once cultures and trajectories clarify etiology. Procalcitonin-guided early discontinuation reduces antibiotic exposure in general critical-care populations; in PCAS, use should prioritize serial trends integrated with clinical context rather than single thresholds. No fixed algorithm is prescribed; instead, practical considerations are presented to guide diagnostic practice, emphasizing early microbiological sampling and imaging, integration of serial biomarker trajectories with clinical assessment, and timely de-escalation as the clinical picture clarifies, without endorsing single-test cutoffs. Priorities include quantifying infection-attributable morbidity and mortality; developing and validating PCAS-specific biomarkers and composite decision tools, including electronic health record-based early warning models; evaluating short post-intubation prophylaxis in selected high-risk patients; optimizing TTM parameters (target temperature, duration, rewarming rate); and systematically characterizing under-recognized infections. A protocol-driven, multimodal program that integrates prevention, standardized diagnostics, and stewardship is required to deliver timely, appropriate therapy and improve outcomes after cardiac arrest.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of combined carbazochrome sodium sulfonate plus tranexamic acid therapy versus tranexamic acid monotherapy in traumatic brain injury: a retrospective cohort study in Japan. 日本的一项回顾性队列研究:卡巴唑胺磺酸钠联合氨甲环酸与氨甲环酸单药治疗外伤性脑损伤的疗效。
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-01-27 DOI: 10.1186/s40560-026-00855-w
Jinsuke Mizuno, Yoshihisa Miyamoto, Yuichiro Matsuo, Kiyohide Fushimi, Ryota Inokuchi, Kent Doi, Hideo Yasunaga

Background: Traumatic brain injury (TBI) is a major public health concern associated with substantial morbidity and mortality. In Japan, carbazochrome sodium sulfonate (CSS) is widely used, often in combination with tranexamic acid (TXA), for the management of various types of bleeding; however, studies on the effectiveness of CSS in TBI are scarce. Therefore, this study aimed to investigate the association between the use of CSS plus TXA versus TXA alone and the clinical outcomes in patients with TBI.

Methods: This observational study was conducted using data retrieved from the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. We enrolled adult patients aged ≥ 16 years diagnosed with TBI who received TXA on the day of admission. Patients with chronic subdural hematoma, suspected TBI diagnosis, or severe extracranial trauma were excluded. The exposure was CSS plus TXA administration on the day of admission, with TXA monotherapy assigned as the control. The primary outcome was 28-day in-hospital mortality, and the secondary outcomes were 7-day in-hospital mortality, overall in-hospital mortality, consciousness at discharge, and length of hospital stay. We used propensity-score overlap weighting to balance patient characteristics between the groups.

Results: This study included 150,026 patients. Of these, 17,212 (11.5%) received TXA alone, and 132,814 (88.5%) received CSS plus TXA. After propensity score overlap weighting, the primary outcome did not differ significantly between the TXA-only and CSS plus TXA groups (11.7% vs. 11.9%; risk difference, 0.1%; 95% CI - 0.4 to 0.7%). The secondary outcomes were also comparable between the two groups. However, the subgroup analysis restricted to unarousable patients (Japan Coma Scale 100-300) revealed a significant reduction in the 7-day mortality in the CSS plus TXA group.

Conclusions: Combined treatment with CSS and TXA was not associated with better clinical outcomes in terms of in-hospital mortality, consciousness at discharge, or length of hospital stay in hospitalized adult patients with TBI compared with TXA therapy alone. Routine use of CSS may not be recommended.

背景:外伤性脑损伤(TBI)是与大量发病率和死亡率相关的主要公共卫生问题。在日本,咔唑铬磺酸钠(CSS)被广泛使用,通常与氨甲环酸(TXA)联合使用,用于治疗各种类型的出血;然而,关于CSS在TBI中的有效性的研究很少。因此,本研究旨在探讨CSS联合TXA与单独使用TXA与TBI患者临床结局之间的关系。方法:本观察性研究使用2010年7月至2022年3月从日本诊断程序组合数据库检索的数据进行。我们招募了年龄≥16岁诊断为TBI并在入院当天接受TXA治疗的成年患者。排除有慢性硬膜下血肿、疑似脑外伤或严重颅外外伤的患者。在入院当天,暴露为CSS加TXA治疗,TXA单药治疗作为对照。主要结局是28天住院死亡率,次要结局是7天住院死亡率、总体住院死亡率、出院时意识和住院时间。我们使用倾向评分重叠加权来平衡各组之间的患者特征。结果:本研究纳入150,026例患者。其中,17212例(11.5%)单独接受TXA治疗,132814例(88.5%)接受CSS加TXA治疗。在倾向评分重叠加权后,主要结局在仅使用TXA和CSS加TXA组之间没有显著差异(11.7% vs 11.9%;风险差异为0.1%;95% CI - 0.4 - 0.7%)。两组间的次要结果也具有可比性。然而,亚组分析仅限于不能醒来的患者(日本昏迷量表100-300),结果显示CSS加TXA组7天死亡率显著降低。结论:与单独TXA治疗相比,在住院成年TBI患者的住院死亡率、出院时意识或住院时间方面,CSS和TXA联合治疗与更好的临床结果无关。不建议常规使用CSS。
{"title":"Outcomes of combined carbazochrome sodium sulfonate plus tranexamic acid therapy versus tranexamic acid monotherapy in traumatic brain injury: a retrospective cohort study in Japan.","authors":"Jinsuke Mizuno, Yoshihisa Miyamoto, Yuichiro Matsuo, Kiyohide Fushimi, Ryota Inokuchi, Kent Doi, Hideo Yasunaga","doi":"10.1186/s40560-026-00855-w","DOIUrl":"https://doi.org/10.1186/s40560-026-00855-w","url":null,"abstract":"<p><strong>Background: </strong>Traumatic brain injury (TBI) is a major public health concern associated with substantial morbidity and mortality. In Japan, carbazochrome sodium sulfonate (CSS) is widely used, often in combination with tranexamic acid (TXA), for the management of various types of bleeding; however, studies on the effectiveness of CSS in TBI are scarce. Therefore, this study aimed to investigate the association between the use of CSS plus TXA versus TXA alone and the clinical outcomes in patients with TBI.</p><p><strong>Methods: </strong>This observational study was conducted using data retrieved from the Japanese Diagnosis Procedure Combination database between July 2010 and March 2022. We enrolled adult patients aged ≥ 16 years diagnosed with TBI who received TXA on the day of admission. Patients with chronic subdural hematoma, suspected TBI diagnosis, or severe extracranial trauma were excluded. The exposure was CSS plus TXA administration on the day of admission, with TXA monotherapy assigned as the control. The primary outcome was 28-day in-hospital mortality, and the secondary outcomes were 7-day in-hospital mortality, overall in-hospital mortality, consciousness at discharge, and length of hospital stay. We used propensity-score overlap weighting to balance patient characteristics between the groups.</p><p><strong>Results: </strong>This study included 150,026 patients. Of these, 17,212 (11.5%) received TXA alone, and 132,814 (88.5%) received CSS plus TXA. After propensity score overlap weighting, the primary outcome did not differ significantly between the TXA-only and CSS plus TXA groups (11.7% vs. 11.9%; risk difference, 0.1%; 95% CI - 0.4 to 0.7%). The secondary outcomes were also comparable between the two groups. However, the subgroup analysis restricted to unarousable patients (Japan Coma Scale 100-300) revealed a significant reduction in the 7-day mortality in the CSS plus TXA group.</p><p><strong>Conclusions: </strong>Combined treatment with CSS and TXA was not associated with better clinical outcomes in terms of in-hospital mortality, consciousness at discharge, or length of hospital stay in hospitalized adult patients with TBI compared with TXA therapy alone. Routine use of CSS may not be recommended.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146064379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comments on: risk factors for nosocomial meningitis in patients with external ventricular drainages. 外脑室引流患者院内性脑膜炎的危险因素
IF 4.7 2区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2026-01-26 DOI: 10.1186/s40560-026-00851-0
Maxime Théo Aparicio, Sylvain Diop, Roman Mounier

In this comment, we aim to offer some perspective on the work of Raffenot et al. entitled "Risk factors for nosocomial meningitis in patients with external ventricular drainages". After highlighting the main findings of their study, we discuss the predictive model as well as the disease definition they used.

在这篇评论中,我们的目的是对Raffenot等人题为“外脑室引流患者院内性脑膜炎的危险因素”的工作提供一些观点。在强调了他们研究的主要发现之后,我们讨论了预测模型以及他们使用的疾病定义。
{"title":"Comments on: risk factors for nosocomial meningitis in patients with external ventricular drainages.","authors":"Maxime Théo Aparicio, Sylvain Diop, Roman Mounier","doi":"10.1186/s40560-026-00851-0","DOIUrl":"10.1186/s40560-026-00851-0","url":null,"abstract":"<p><p>In this comment, we aim to offer some perspective on the work of Raffenot et al. entitled \"Risk factors for nosocomial meningitis in patients with external ventricular drainages\". After highlighting the main findings of their study, we discuss the predictive model as well as the disease definition they used.</p>","PeriodicalId":16123,"journal":{"name":"Journal of Intensive Care","volume":"14 1","pages":"7"},"PeriodicalIF":4.7,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146052508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Intensive Care
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1